CONCERTA/Methylphenidate — Percent Change (as a percent)
Johnson & Johnson CONCERTA/Methylphenidate — Percent Change (as a percent) decreased by 196.3% to -8.0% in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 50.9%, from -16.3% to -8.0%. Over 2 years (FY 2021 to FY 2025), CONCERTA/Methylphenidate — Percent Change (as a percent) shows a downward trend with a 12.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
A positive percentage indicates revenue growth and strong market positioning, whereas a negative percentage suggests declining demand, market saturation, or loss of exclusivity.
Detailed definition
This metric measures the period-over-period percentage growth or decline in net sales for the Concerta and methylphenida...
Peer comparison
Comparable to year-over-year or sequential revenue growth rates for specific pharmaceutical products reported by other healthcare companies.
jnj_segment_concerta_methylphenidate_percent_change_as_a_percentHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 8.1% | 4.5% | 3.2% | -8.3% | 0.3% | 0.8% | -1% | 31.4% | 28.6% | 20% | -14.1% | -21.5% | -24.8% | -16.3% | 0.2% | -1.4% | -2.7% | -8% |
| QoQ Change | — | -44.4% | -28.9% | -359.4% | +103.6% | +166.7% | -225.0% | >999% | -8.9% | -30.1% | -170.5% | -52.5% | -15.3% | +34.3% | +101.2% | -800.0% | -92.9% | -196.3% |
| YoY Change | — | — | — | — | -96.3% | -82.2% | -131.3% | +478.3% | >999% | >999% | -144.9% | -175.2% | -224.0% | -15.6% | +100.9% | +94.4% | — | +50.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's concerta/methylphenidate — percent change (as a percent)?
- Johnson & Johnson (JNJ) reported concerta/methylphenidate — percent change (as a percent) of -8.0% in Q1 2026.
- How has Johnson & Johnson's concerta/methylphenidate — percent change (as a percent) changed year-over-year?
- Johnson & Johnson's concerta/methylphenidate — percent change (as a percent) increased by 50.9% year-over-year, from -16.3% to -8.0%.
- What is the long-term trend for Johnson & Johnson's concerta/methylphenidate — percent change (as a percent)?
- Over 2 years (2021 to 2025), Johnson & Johnson's concerta/methylphenidate — percent change (as a percent) has grown at a 12.4% compound annual growth rate (CAGR), from 16.0% to -20.2%.
- What does concerta/methylphenidate — percent change (as a percent) mean?
- The percentage change in revenue for Concerta and methylphenidate products compared to the previous period.